Navigation Links
InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
Date:8/20/2008

$1,417,079 $813,322

InstaCare Corp.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

Revenue $3,020,694 $1,036,849 $5,818,076 $2,120,131

Cost of sales 2,676,063 908,652 5,025,946 1,797,304

Gross profit 344,631 128,197 792,130 322,827

Expenses:

General &

administrative 64,558 78,967 125,304 181,526

Consulting 28,442 119,810 93,735 378,077

Payroll expense 79,815 34,664 200,335 87,898

Professional fees 22,240 57,486 67,596 81,976

Depreciation and

amortization 9,063 11,745 18,126 23,490

Total expenses 204,118 302,672 505,096 752,967

Net operating income

(loss) 140,513 (174,475) 287,034 (430,140)

Other income

(expense):

Contingent expenses - 81,600 - -

Financing costs (66,786) (1,907) (116,260) (11,123)

Interest expense,

net (56,075) (55,788) (111,393) (112,493)

Total other

income

(expense) (122,861) 23,905 (227,653) (123,616)

Net income (loss) 17,652 (150,570) 59,381 (553,756)

Add: Dividends

declared on

preferred - - - -

Income (loss)

available to

common

shareholders' $17,652 $(150,570) $59,381 $
'/>"/>

SOURCE InstaCare Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
3. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
4. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
5. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
6. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
7. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
8. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
9. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
10. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
11. CellCyte Genetics Corp. Appoints Jay H. Traverse to Scientific Advisory Board as Clinical Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MESSENGER has just celebrated its 10 year anniversary in ... of its latch valves, V27200-818, operating onboard this spacecraft. ... the planet Mercury. It is only the second spacecraft ... vast amount of information and images of the planet. ... that also include permanent magnets to maintain the valve ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... a deicing film for radar domes have now refined ... glass. , The new work by Rice chemist ... from windshields to skyscrapers free of ice and fog ... , The technology was introduced this month in the ... . , The material is made of graphene ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... -- As open enrollment season approaches, U.S. employees will soon ... benefits. According to Aon Hewitt , the global ... plc (NYSE: AON ), employees will ... managing their health care decisions. This increased responsibility makes ... how they can make the most of the programs ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 2Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 3Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 4Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 5Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 6Aon Hewitt Provides Tips to Help Workers Prepare for the Upcoming Open Enrollment Season 7
... "crack baby" hysteria of the 1980s was greatly ... but disabling cognitive impairments -- attention deficits, learning ... study by investigators at the Vanderbilt Kennedy Center ... the long-term behavioral and neurological problems associated with ...
... especially those that are hydrophobic or water-repellant, to tumors ... develop innovative delivery systems that keep these drugs intact ... University at Buffalo’s Institute for Lasers, Photonics and Biophotonics ... solution in which the delivery system is the drug ...
... Researchers have linked a structural protein called nestin to ... new biomarker that could lead to earlier detection and ... of Cancer Research, researchers from Dartmouth Medical School demonstrate ... basal epithelial breast tumors, a highly aggressive cancer with ...
Cached Biology News:Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3No carrier necessary: This drug delivers itself 2Selective marker found to indicate aggressive form of breast cancer 2
... The Neural Stem Cell Expansion Kit - ... in vitro NSC expansion as a monolayer ... specially formulated N-2 Plus Media Supplement, which has ... K.K. et al . (1996) Genes & ...
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
... Fragment is a genetically engineered Klenow polymerase in ... been removed, leaving only the 5 to 3 ... Exo- Klenow Fragment the enzyme of choice for ... the random primed method, and for DNA sequencing ...
... RNA polymerase is a DNA-dependent RNA polymerase ... promoters. It efficiently synthesizes in vitro ... down stream from a T7 promoter. ... templates for in vitro translation, substrates in ...
Biology Products: